الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 81 |  |  |
| | | from | 81 | | |
Abstract
ESKD is a major problem in public health around the world since it is becoming more common, requires costly treatments, and causes a lot of sickness and death. Treatment options for end-stage kidney disease (ESKD) include kidney transplant (KTx), hemodialysis, and peritoneal dialysis.
Finding out how mycophenolate mofetil (MMF) and mycophenolate sodium (MPS) interact with tacrolimus in a kidney transplant patient is the main goal of this research.
A total of 300 participants were included in this case-control research. Minia University Hospital’s outpatient clinic will be the source of potential participants.
There are two groups into which the subjects fall:
A total of 150 patients undergoing maintenance pharmacotherapy for solid organ transplantation (MPS) after a kidney transplant make up group I.
group II includes 150 patients who are presently using MFF medicine and have undergone a kidney transplant.
The two groups were compared by us:
1-Both sets of participants had a rejection rate
Symptoms of 2-GIT were present in both groups.
All patients are required to undergo:
1- Thorough medical evaluation
Why is it necessary to transplant kidneys?
Issues with the gastrointestinal tract after a kidney transplant
A complete blood count (CBC), evaluation of uric acid levels, testing of renal function, analysis of urine, and measurement of calcium and phosphorus levels are all part of the standard laboratory examinations.
Patient characteristics and outcome evaluation criteria
Demographic information was collected from patients, including their gender, age, medication consumption, weight, height, BMI, and the age of the donors. In order to evaluate their effects on transplant results, the study also considered the recipient-donor relationship, ABO incompatibility, transplant type, HLA mismatch, anti-thymocyte globulin (ATG) induction, and the time between the transplant and the year data was collected.
When comparing the two groups according to body mass index and dosage twice, a p-value of less than 0.001 indicates a statistically significant difference.
Regarding the remaining demographic variables, no statistically significant variations were found between the two sets of data.
The p-value for the difference in S.Cr and a/c ratio between the two groups was less than 0.001, indicating a statistically significant difference.
Other laboratory result parameters did not show a statistically significant difference between the two groups.
In all other aspects of the clinical data, no statistically significant difference was found between the two groups.
In conclusion no significant disparities in terms of side effects and effectiveness were noted between MMF and MPS. The dosage of Maintenance MPS was more than that of MMF. Administering greater amounts can lead to enhanced immunosuppression. Nevertheless, our study did not see any disparity in the effectiveness of the two treatment protocols. When selecting a mycophenolic acid derivative, economic factors may play a significant role.